drugset
drugset / Trial / NCT04931459

A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

NCT04931459 ↗

Phase 1 Completed 65 enrolled Acumen Pharmaceuticals National Institute on Aging (NIA) · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when administered to participants diagnosed with Mild Cognitive Impairment (MCI) or Mild Dementia due to Alzheimer's disease (AD).

Timeline

Start
2021-06-21
Primary completion
2023-06-12
Completion
2023-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject sabirnetug Monoclonal antibody — Intravenous

Indications

Alzheimer disease